Company news

BELLUS Health Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

BELLUS Health reports results for the year ended December 31, 2014

February 25, 2015

BELLUS Health announces sale of ABCP Notes and settlement of credit facilities

November 26, 2014

Bellus Health Reports Results for Third Quarter Ended September 30, 2014

November 5, 2014

BELLUS Health Reports Results for Second Quarter Ended June 30, 2014

August 13, 2014

Auven Therapeutics and BELLUS Health announce completion of enrollment in the Phase III Confirmatory Study of KIACTA(TM) for the treatment of AA amyloidosis

May 27, 2014

BELLUS Health reports results for first quarter ended March 31, 2014, and provides update on rare disease pipeline

May 7, 2014

Auven Therapeutics and BELLUS Health Announce Engagement of Financial Advisor to Explore Sale of KIACTA(TM), an Experimental Drug in Phase III Development for the Treatment Of AA Amyloidosis

May 7, 2014

Auven Therapeutics and BELLUS Health Announce Licence Agreement with Mount Sinai for KIACTA(TM) in Sarcoidosis

May 2, 2014

BELLUS Health reports results for year ended December 31, 2013

February 26, 2014

BELLUS Health provides update on KIACTA(TM) Phase III orphan drug study

January 9, 2014

BELLUS Health reports results for third quarter ended September 30, 2013

November 5, 2013

BELLUS Health and AmorChem Announce a Partnership to Develop Drug Candidates for AL Amyloidosis

October 28, 2013

BELLUS Health Out-Licenses VIVIMIND, BLU8499 and Its Analogs

October 23, 2013

BELLUS Health announces closing of the acquisition of Thallion Pharmaceuticals

August 15, 2013

BELLUS Health reports results for second quarter ended June 30, 2013

August 7, 2013

KIACTA(TM) Granted Orphan Drug Status in Japan

July 23, 2013

BELLUS Health to acquire Thallion Pharmaceuticals

June 18, 2013

BELLUS Health Reports Results for First Quarter Ended March 31, 2013, and Provides Update on KIACTA(TM) Phase III Confirmatory Study

May 15, 2013

BELLUS Health Reports Results for Year Ended December 31, 2012

February 27, 2013

BELLUS Health Reports Results for Third Quarter Ended September 30, 2012, and Provides an Update on KIACTA(TM) Phase III Confirmatory Study

November 8, 2012

BELLUS Health to Present at BioContact in Québec City

October 1, 2012

BELLUS Health Announces Partnership for the Development of BLU8499

September 4, 2012

BELLUS Health Reports Results for Second Quarter Ended June 30, 2012

August 8, 2012

BELLUS Health Receives Milestone Payment from Advanced Orthomolecular Research

June 21, 2012

Bellus Health to Present at Bloom Burton & Co. Healthcare Investor Conference

June 6, 2012

Bellus Health to Present at BioFinance 2012

May 25, 2012

Bellus Health and Pharmascience Announce Closing of $17.25M Transaction

May 25, 2012

BELLUS Health Securityholders Vote in Favour Of $17.25 Million Strategic Transaction with Pharmascience

May 15, 2012

BELLUS Health announces update on the Phase III trial for KIACTA(tm) in AA amyloidosis presented at the XIII International Symposium on Amyloidosis

May 10, 2012

BELLUS Health Announces Share Consolidation and Record Date for Annual and Special Meeting of Securityholders

April 19, 2012

BELLUS Health announces a $17 million strategic partnership and financing with Pharmascience Inc.

April 5, 2012

BELLUS Health reports results for year ended December 31, 2011, and provides update on KIACTA(tm) phase 3 confirmatory study

February 22, 2012

BELLUS Health and Integris Pharma Ltd. enter into exclusive license agreement for VIVIMIND(tm) in Greece and Cyprus

December 1, 2011

OVOS Natural Health Inc. launches VIVIMIND(tm) in Canada

November 28, 2011

BELLUS Health reports results for third quarter ended September 30, 2011, and provides update on VIVIMIND(tm) partnerships

November 9, 2011

BELLUS Health reports results for second quarter ended June 30, 2011

August 10, 2011

Crystal Research Associates Issues Research Report on BELLUS Health Inc.

July 13, 2011

BELLUS Health reports results for first quarter ended March 31, 2011

June 8, 2011

BELLUS Health delivering on key strategic partnerships and KIACTA(tm) phase III development

May 11, 2011

BELLUS Health issues shares in final payment for the exercise of its lease termination option

April 7, 2011

BELLUS Health and the agahan group enter into broad license for VIVIMIND(tm) in the Middle East

April 4, 2011

BELLUS Health completes restructuring initiatives with repatriation of intellectual property to canada

March 31, 2011

BELLUS Health reports results for fourth quarter and year ended December 31, 2010

February 23, 2011

BELLUS Health announces phase i results of prodrug NRM8499 intended for the treatment of Alzheimer's disease

January 31, 2011

BELLUS Health exercises option to terminate lease

January 14, 2011

Advanced orthomolecular research acquires BELLUS Health's Canadian subsidiary OVOS natural health

January 4, 2011

Crystal Research Associates Issues Updated Report on BELLUS Health Inc.

December 16, 2010

Celtic Therapeutics and BELLUS Health initiate confirmatory phase III clinical study for KIACTA?, a drug candidate for the treatment of AA amyloidosis

December 15, 2010

BELLUS Health reports results for third quarter ended September 30, 2010 and announces receipt of US$5 million from partner celtic therapeutics

November 10, 2010

BELLUS Health and FB health enter agreement for BELLUS' VIVIMIND¿ in Italy

October 19, 2010

← Newer news releases · Older news releases →

Decks